Argenx agreed to acquire Unnatural Products for $550 million up front, expanding its immunology platform with a macrocyclic peptide discovery engine aimed at developing oral peptide therapeutics. The transaction adds a non-antibody modality to Argenx’s existing pipeline direction and supports continued platform diversification. The acquisition follows a strategy shift in which large biopharma and advanced biotechs increasingly seek distinct chemistry and delivery competencies—particularly for oral biologics—while using acquisitions to compress modality-learning curves. For the market, the deal highlights investor appetite for peptide ecosystems and suggests that oral administration remains a high-value differentiator that can change competitive dynamics in immunology franchises.